High Throughput 96- & 384-Well DNA Purificati?on
MagSi-DNA cleanFIX from AMSBIO offers a cost effective solution for purifying DNA fragments, removing all unwanted side products and reagents, such as single nucleotides, terminator dyes, primers and primer dimers, enzymes, buffers and salts.
In many genomics applications, purification of DNA fragments is required to prevent downstream interference with analysis methods. Purification of PCR reactions often requires removal of dNTPs, primers, enzymes, salt by-products and various additives. Historically purification protocols have involved different sample types, different volumes and often multiple washing and centrifugation steps. Using such methods the errors incurred during sample preparation have resulted in lost time and significant costs due to re-work and lost reagents.
MagSi-DNA cleanFIX enables a combination of PCR clean-up and dye terminator removal from sequence reaction mixes with a single product. The kit uses magnetic silica bead technology, and is easily automated because no columns or centrifugation steps are involved. The kit uses a simple “Bind, Wash & Elute” procedure common to magnetic particle purification protocols.
Independent test results demonstrate how MagSi-DNA cleanFIX purification methods developed for a commercial liquid handling workstation provide an automated walk-away solution for PCR clean-up and dye terminator removal from sequence reactions. The precision and reproducibility of the workstation in combination with the customized magnets for MagSi-DNA cleanFIX are shown to allow fast magnetic separation and homogenization of the samples. Overall the PCR clean-up protocol using MagSi-DNA cleanFIX is shown to enable fast and efficient recovery of DNA fragments larger than 80 bp with >99% removal of primers and primer dimers. In addition the dye terminator removal method consistently delivered high quality sequence data with Phred >20 scores above 700.
For further information on MagSi-DNA cleanFIX and the fully range of magnetic beads available from AMSBIO please visit www.amsbio.com/DNA-sequencing-
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.